Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

被引：0

作者：

Even, C. ^{[1
]}

Bernard-Tessier, A. ^{[2
]}

Texier, M. ^{[3
]}

Said, O. Ben ^{[4
]}

Iacob, M. ^{[5
]}

Daste, A. ^{[6
]}

Fayette, J. ^{[7
]}

Zanetta, S. ^{[8
]}

Lefebvre, G. ^{[9
]}

Vinches, M. ^{[10
]}

Johnson, A. C. ^{[11
]}

Le Moal, L. Bozec ^{[12
]}

Saada, E. B. ^{[13
]}

Jallut, I. ^{[14
]}

Garic, F. ^{[15
]}

Monard, L. ^{[16
]}

Bourhis, J. ^{[17
]}

Guigay, J. ^{[18
]}

Auperin, A. ^{[19
]}

Ammari, S. ^{[20
]}

机构：

[1] Inst Gustave Roussy, Head & Neck Oncol Dept, Villejuif, France

[2] Inst Gustave Roussy, Oncol Dept, Villejuif, France

[3] Inst Gustave Roussy, Biostat & Epidemiol, Villejuif, France

[4] Gustave Roussy, Radiol, Canc Campus, Villejuif, France

[5] IRO Reg Inst Oncol, Med Oncol Dept, Villejuif, France

[6] CHU Bordeaux, Med Oncol Dept, Hop St Andre, Bordeaux, France

[7] Ctr Leon Berard, Med Oncol Dept, Lyon, France

[8] Ctr Georges Francois Leclerc Dijon, Med Oncol Dept, Dijon, France

[9] Ctr Oscar Lambret, Med Oncol Dept, Lille, France

[10] ICM Inst Canc Montpellier, Med Oncol Dept, Montpellier, France

[11] Ctr Francois Baclesse, Med Oncol Dept, Caen, France

[12] Hop Rene Huguenin, Inst Curie, Med Oncol Dept, St Cloud, France

[13] Ctr Anticancer Antoine Lacassagne, Med Oncol, Nice, France

[14] Unicancer, R&D, Paris, France

[15] Unicancer, Paris, France

[16] Unicancer, UCGI R&D, Paris, France

[17] CHU Vaudois, Radiat Oncol Dept, UNIL CHUV, Lausanne, Switzerland

[18] Ctr Anticancer Antoine Lacassagne, Med Oncol Dept, Nice, France

[19] Gustave Roussy, Biostat & Epidemiol, Canc Campus, Villejuif, France

[20] Gustave Roussy, Med Oncol Dept, Canc Campus, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.799

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

675P

引用

页码：S851 / S851

页数：1

共 50 条

[41] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
Chung, Christine H.
Bonomi, Marcelo Raul
Steuer, Conor Ernst
Schell, Michael J.
Li, Jiannong
Johnson, Matthew
Masannat, Jude
Hernandez-Prera, Juan C.
McMullen, Caitlin
Wadsworth, J.
Patel, Krupal
Kish, Julie Ann
Muzaffar, Jameel
Kirtane, Kedar
Rocco, James William
Saba, Nabil F.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[42] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Bauman, Julie E.
Roe, Denise
Saba, Nabil F.
Bauman, Jessica Ruth
Kaczmar, John M.
Burtness, Barbara
Muzaffar, Jameel
Julian, Ricklie Ann
Wang, Steven
Bearelly, Shethal
Baker, Audrey
Steuer, Conor Ernst
Bhatia, Aarti K.
Giri, Anshu
Caulin, Carlos
Stabile, Laura P.
Centuori, Sara
Chung, Christine H.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[43] Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Saada-Bouzid, E.
Defaucheux, C.
Karabajakian, A.
Coloma, V. P.
Servois, V.
Paoletti, X.
Even, C.
Fayette, J.
Guigay, J.
Loirat, D.
Peyrade, F.
Alt, M.
Gal, J.
Le Tourneau, C.
ANNALS OF ONCOLOGY, 2017, 28 (07) : 1605 - 1611
[44] A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
Ho, A. L.
Adkins, D. R.
Hanna, G. J.
Bruce, J.
Ahn, M. J.
Docampo, L. Iglesias
Kang, H.
Wong, D. J.
Psyrri, A.
Gillison, M.
Brana, I.
Liu, Y. C.
Hsieh, C. Y.
Hong, M. H.
Zhang, Z.
Balsara, B.
Saunders, A.
Hernandez, A. Gasco
Dale, S.
Haddad, R.
ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1287
[45] Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre
Siano, M.
Desax, M. C.
Frueh, M.
Joerger, M.
Oncology Research and Treatment, 2015, 38 : 186 - 186
[46] ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
Fayette, J.
Saada, E. B.
DeMontfort, A.
Karabajakian, A.
Neidhardt, E. M.
Borel, C.
Burgy, M.
Carinato, H.
Delord, J-P.
Betrian, S.
Toussaint, P.
Chatellier, T.
Iharidon, T.
Garin, G.
Bernardin, M.
Jaouen, L.
Sondarjee, I.
Perol, D.
Blay, J-Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S851 - S852
[47] Impact of ECOG performance status on recurrent/metastatic head and neck squamous cell carcinomas treated with anti-PD1 inhibitors.
Chalker, Cameron
Wu, Vicky
Voutsinas, Jenna M.
Hwang, Victoria
Baik, Christina S.
Liao, Jay Justin
Lee, Sylvia
Futran, Neal D.
Houlton, Jeffrey
Barber, Brittany
Parvathaneni, Upendra
Laramore, George E.
Santana-Davila, Rafael
Eaton, Keith D.
Martins, Renato G.
Rodriguez, Cristina P.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study
Guo, Y.
Li, D. Z.
Lin, J.
Sun, C.
Cao, G.
Wu, J.
Ge, M.
Hu, D.
Qu, S.
Shen, L.
Wei, Y.
Zong, J.
Fang, M.
Jin, C.
Li, Z-M.
Sun, Y.
Wang, X.
Zhang, H.
Wang, W.
Zhu, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S625 - S625
[49] Carboplatin and paclitaxel after anti-PD1 or anti-PDL1 therapy: A retrospective study in patients with squamous cell carcinoma of the head and neck
Humphries, Audrey
Welsh, Madeleine
Algazi, Alain
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[50] A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC
Colevas, A. Dimitrios Dimitrios
Dinis, Jose Prime
Chin, Venessa T.
Costa, Diogo Alpuim
Park, John J.
Fang, Bruno
Phan, Minh Duc
Zhang, Yiran
U'Ren, Lance
Odegard, Jared
Curtis, Kelly Kevelin
Pirtle, Erika
Adkins, Douglas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →